$1.75
-0.57%NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NBP • NASDAQ
| NovaBridge Biosciences Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
0.0 | 0.0 | 4.5M | -10.7M | 88M | 1.5B | 30M | 53.8M | 11.6M | |
GROSS PROFIT | |||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (46.4M) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 4.5M | -10.7M | 41.6M | 1.5B | 30M | 53.8M | 11.6M | |
OPERATING INCOME | |||||||||
(13.5M) | (375.4M) | (515.6M) | (355.4M) | (2.1B) | (1.4B) | (1.5B) | (461.4M) | (310.6M) | |
(4.5M) | (216.5M) | (63.9M) | (199.9M) | (899.9M) | (402.4M) | (654.6M) | (66.4M) | (25.4M) | |
(9M) | (158.9M) | (114.4M) | (155.5M) | (190.3M) | (984.7M) | (840.4M) | (426M) | (267.1M) | |
-13.5M | -375.4M | -511.2M | -366.1M | -2.1B | 155.6M | -1.5B | -438.6M | -281M | |
PRE-TAX INCOME | |||||||||
(0.0) | (0.0) | (101.9K) | (0.0) | (0.0) | (146.5K) | (427.5K) | (1.7M) | (864.3K) | |
1.1M | 54.6M | 7.2M | 5M | 21.3M | 3.6M | 3.9M | -1M | -732.9K | |
(0.0) | (0.0) | (337.4M) | -247.0 | (1B) | (0.0) | (14.6M) | (0.0) | (0.0) | |
847.6K | 12.6M | -954.5M | -607.1M | -260.7M | 327.6M | 13M | 37.5M | -17.3M | |
-12.6M | -362.7M | -1.5B | -973.2M | -2.3B | 483.1M | -1.5B | -401.1M | -298.2M | |
NET INCOME | |||||||||
(0.0) | (0.0) | -1.3B | (710.4K) | -494.8K | (12.2M) | (0.0) | (1.7M) | (0.0) | |
-6.6M | -162.3M | -1.5B | -2.5B | -2.3B | 470.9M | -1.5B | -402.8M | -298.2M |
NBP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
6-K 6-K 2026 Q2 Q2 | April 22, 2026 | April 22, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | April 07, 2026 | April 07, 2026 | 2026 | |
20-F 20-F 2025 FY FY | April 07, 2026 | December 31, 2025 | 2025 | |
6-K 6-K 2026 Q1 Q1 | March 16, 2026 | March 16, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | March 09, 2026 | March 09, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | March 03, 2026 | March 03, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | February 25, 2026 | February 25, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | February 19, 2026 | February 19, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | February 17, 2026 | February 17, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | February 06, 2026 | February 06, 2026 | 2026 |
Continue your NBP research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.